Journal
JOURNAL OF MEDICINAL CHEMISTRY
Volume 60, Issue 23, Pages 9575-9584Publisher
AMER CHEMICAL SOC
DOI: 10.1021/acs.jmedchem.7b00994
Keywords
-
Categories
Funding
- MINECO [SAF2013-48271-C2, SAF2014-57138-C2-2-R, SAF2016-78792-R, INNPACTO 01/12-CL-0-12-09]
- CAM [S2010/BMD2353]
- Xunta de Galicia [GRC2014/011]
- Junta de Andalucia [CTS-8221, CTS-433]
- European Regional Development Fund (ERDF)
- MINECO
Ask authors/readers for more resources
The 5-HT2CR. agonist lorcaserin, clinically approved for the treatment of obesity; causes important side effects mainly related to subtype selectivity. In the search for 5-HT2CR allosteric modulators as safer antiobesity drugs, a chemical library from Vivia Biotech was screened using ExviTech platform. Structural modifications of identified hit VA240 in synthesized analogues 6-41 afforded compound 11 (N-[(1-benzy1-1H-inclo1-3-yl)methyl]pyridin-3-amine, VA012), which exhibited dose-dependent enhancement of serotonin efficacy, no significant off-target activities, and low binding competition with serotonin or other orthosteric ligands. PAM 11 was very active in feeding inhibition in rodents, an effect that was not related to the activation of 5-HT2AR. A combination of 11 with the SSRI sertraline increased the anorectic effect. Subchronic administration of 11 reduced food intake and body weight gain without causing CNS-related malaise. The behavior of compound 11 identified in this work supports the interest of a serotonin 5-HT2CR PAM as a promising therapeutic approach for obesity.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available